Related Experiment Video
Updated: Mar 17, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
2.7K
[Rectal gastrointestinal stromal tumor: a clinical and pathologic analysis]
1Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
Summary
Rectal gastrointestinal stromal tumors (GISTs) are rare, often asymptomatic, and typically present in males. Treatment with imatinib can reduce tumor size and improve histological features, aiding in sphincter preservation.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Rectal gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms.
- Understanding their clinicopathologic features is crucial for effective management.
Purpose of the Study:
- To investigate the clinicopathologic characteristics and therapeutic outcomes of rectal GISTs.
- To evaluate the efficacy of imatinib therapy in rectal GISTs.
Main Methods:
- Retrospective analysis of 53 cases (58 samples) of rectal GISTs.
- Review of clinical data, morphology, immunophenotype, and prognosis.
- Assessment of treatment responses, including imatinib therapy.
Main Results:
- The study included 53 patients (33 male, 20 female) with rectal GISTs.
- Most tumors were diagnosed incidentally or presented with rectal symptoms; imatinib therapy reduced tumor size and altered histology.
- Risk stratification revealed a significant proportion of high-risk tumors, with recurrent cases showing increased cellularity and mitotic activity.
Conclusions:
- Rectal GISTs are rare, predominantly affect males, and are often asymptomatic.
- Diagnosis is typically made via biopsy, and preoperative therapy, including imatinib, can be beneficial for sphincter preservation.
- Risk stratification and appropriate therapy are essential for managing rectal GISTs.
